The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques
2014; Microbiology Society; Volume: 95; Issue: 10 Linguagem: Inglês
10.1099/vir.0.067835-0
ISSN1465-2099
AutoresWendy A. Burgers, Zekarias Ginbot, Yen-Ju Shen, Gerald K. Chege, Andreia Soares, Tracey L. Müller, Rubina Bunjun, Agano Kiravu, Henry Munyanduki, Nicola Douglass, Anna‐Lise Williamson,
Tópico(s)Virus-based gene therapy research
ResumoPoxvirus vectors represent promising human immunodeficiency virus (HIV) vaccine candidates and were a component of the only successful HIV vaccine efficacy trial to date. We tested the immunogenicity of a novel recombinant capripoxvirus vector, lumpy skin disease virus (LSDV), in combination with modified vaccinia Ankara (MVA), both expressing genes from HIV-1. Here, we demonstrated that the combination regimen was immunogenic in rhesus macaques, inducing high-magnitude, broad and balanced CD4(+) and CD8(+) T-cell responses, and transient activation of the immune response. These studies support further development of LSDV as a vaccine vector.
Referência(s)